Study of the Effect of GS-6615 in Subjects With LQT-3

Long QT Syndrome Clinical Trial

Official title:

An Open-label Study to Evaluate the Effect of Single Dose GS-6615 on QT, Safety and Tolerability in Subjects With Long QT-3 Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01849003
• Other study ID #: GS-US-279-0110
• Status: Completed
• Phase: Phase 1
• First received: May 6, 2013
• Last updated: November 13, 2014
• Start date: May 2013
• Est. completion date: November 2014

Study information

• Verified date: November 2014
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This mechanism of action study is to evaluate the effect of oral GS-6615 on the QTc interval in participants with Long QT-3 syndrome. This study will be performed in six cohorts of participants in a sequential manner, four single-dose cohorts followed by two multiple-dose cohorts. Duration of treatment for the single-dose cohorts and multiple-dose cohorts will be 1 day and 7 days, respectively. Participants will be confined at the study center from check-in until completion of assessments at discharge.

Participants will be continuously monitored using real-time telemetry throughout the in-clinic confinement. Physical examinations including vital signs, laboratory analysis, electrocardiograms (ECGs), Holter recordings and echocardiography (ECHO) will be performed at defined time points throughout the study period. Assessment of adverse events and concomitant medications will continue throughout the duration of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Males and females between ages 18-65 years (inclusive) at time of screening

2. Documented LQT-3 genotype with one of the following mutations: delta KPQ, R1623Q, N1325S, E1784K, S1787N, D1790G, G1631D, 1795insD, delF1617, R1644H, L409P, F2004L, I1768V, T1304M, A1330T, or F1596I3.

3. QTc > 480 msec in lead V5 at screening

4. Weight of at least 50 kg with body mass index (BMI) between 18 and 30 kg/m^2 (inclusive)

5. Females of childbearing potential must have a negative serum pregnancy test at screening and check-in

6. Females of childbearing potential must agree to utilize protocol recommended highly effective contraception methods from three weeks prior to the single dose of study drug and for 30 days following the single dose of study drug

a. Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least 3 months prior to study dosing

7. Males must agree to utilize a protocol recommended highly effective method of contraception during heterosexual intercourse throughout the study period and for 90 days following last dose of study drug. Periodic abstinence and withdrawal are not acceptable methods of contraception

8. Males must refrain from sperm donation from Day -2 through completion of the study and continuing for at least 90 days from the date of last dose of study drug

9. Willing and able to comply with the requirements of the protocol and directions from the clinic staff

10. Willing to avoid consumption of grapefruit, grapefruit juice and Seville oranges within 2 weeks prior to the single dose of study drug until discharge from the clinic

11. Willing to avoid consumption of nicotine (including nicotine gum) and alcoholic beverages within 2 weeks prior to the single dose of study drug until discharge from the clinic

12. Understand and willing to sign informed consent

Exclusion Criteria:

1. Ongoing or history of any medical or surgical condition that, in the judgment of the Investigator, might jeopardize the individual's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug

2. History of meningitis or encephalitis, seizures, migraines, tremors, myoclonic jerks, sleep disorder, anxiety, syncope, head injuries or a family history of seizures

3. Any abnormal electrocardiographic (ECG) findings (except QTc > 460 msec) at screening judged to be clinically significant by the investigator

4. Any abnormal laboratory value or physical examination finding at screening or check-in that is judged by the investigator as clinically significant

5. History of positive serology test for HIV, or hepatitis B or C

6. Positive urine drug test for ethanol, barbiturates, cocaine, opiates, or amphetamines at screening or check-in

7. Positive urine cotinine test at check-in

8. Current treatment with drugs affecting the QT interval

9. Current treatment with sodium-channel blockers, eg, flecainide and mexiletine

10. Current treatment with strong or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 and 1A2

11. Prior treatment with ranolazine within 7 days prior to study drug administration

12. Use of systemic prescription medications or over-the-counter (OTC) medication, including multivitamins, and dietary and herbal supplement within 2 weeks or 5 times the terminal half-lives of the medication (whichever is longer) prior to the single dose of study drug, and for the duration of the study

13. Use of any experimental or investigational drug or device within 30 days prior to the single dose of study drug or 5 half-lives of the drug, whichever is longer

14. Females who are pregnant or lactating

15. History of drug or alcohol abuse within 12 months prior to initial dosing of study drug

16. Psychosocial or addictive disorders that would interfere with ability to give informed consent or could compromise compliance with the protocol

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Long QT Syndrome
• Syndrome

Intervention

Drug:
• GS-6615
GS-6615 tablet(s) administered orally

Locations

Country	Name	City	State
United States	University of Rochester Medical Center/Strong Memorial Hospital	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in QTc intervals (Fridericia formula)	Changes in QTc intervals (Fridericia formula; QTcF) from the time-matched ECG in the primary lead V5. In case QT cannot be measured in lead V5, lead II will be designated as the primary lead; Change from the time-matched ECG on Day -1 to Day 1 for Cohorts 1-4; Change from the time-matched ECG average of Day -1 and Day -2 to Days 1-7 for Cohort 5 and 6	Baseline through Day 7	No
Secondary	Incidence of Adverse Events (AEs)		Baseline through Day 22	No
Secondary	Changes in ECHO parameters	ECHO parameters relevant for measurement of diastolic function will be assessed.	Baseline through Day 7	No
Secondary	Area under the plasma concentration-time curve (AUC) from time 0 to the last quantifiable concentration of GS-6615		Baseline through Day 12	No
Secondary	Maximum observed plasma concentration (Cmax) of GS-6615		Baseline through Day 12	No
Secondary	Time to maximum observed concentration (Tmax) of GS-6615		Baseline through Day 12	No
Secondary	Changes in ECG parameters	ECG parameters assessed will include PR, RR, QRS, and QT.; PR: electrocardiographic interval occurring between the onset of the P wave and the QRS complex representing time for atrial and ventricular depolarization, respectively; RR: electrocardiographic interval representing the time measurement between the R wave of one heartbeat and the R wave of the preceding heartbeat; QRS: electrocardiographic deflection between the beginning of the Q wave and termination of the S wave representing time for ventricular depolarization; QT: electrocardiographic interval between the beginning of the Q wave and termination of the T wave representing the time for both ventricular depolarization and repolarization to occur	Baseline through Day 12	No
Secondary	Changes in QTc interval (Bazett [QTcB])	Changes in QTcB from the time-matched ECG in the primary lead V5. In case QT cannot be measured in lead V5, lead II will be designated as the primary lead; Change from the time-matched ECG on Day -1 to Day 1 for Cohorts 1-4; Change from the time-matched ECG average of Day -1 and Day -2 to Days 1-7 for Cohort 5 and 6	Baseline through Day 7	No